Giredestrant vs Vepdegestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Giredestrant

Marketed by Roche

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04546009 · Phase 3 · active, not recruiting

This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.

Next expected readout: July 2027 · NCT03332797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)

Result source: NCT04546009

Vepdegestrant · Veppanu

Marketed by Rigel Pharmaceuticals and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05654623 · Phase 3 · active, not recruiting

Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.

Next expected readout: December 2026 · NCT05909397 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)

Result source: NCT05654623

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointGiredestrantVepdegestrant
PFS, median—Trial running · NCT060657483.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result
OS, median—Trial running · NCT06065748—Trial running · NCT05909397
ORR—Trial running · NCT0606574810.9% vs 3.6%vs Fulvestrantn 221NCT05654623
Clinical benefit rate—Trial running · NCT0606574834.3% vs 28.7%vs Fulvestrantn 274NCT05654623

PFS, median

Giredestrant
—Trial running · NCT06065748
Vepdegestrant
3.7 vs 3.6vs Fulvestrantn 313NCT05654623
1 other result

OS, median

Giredestrant
—Trial running · NCT06065748
Vepdegestrant
—Trial running · NCT05909397

ORR

Giredestrant
—Trial running · NCT06065748
Vepdegestrant
10.9% vs 3.6%vs Fulvestrantn 221NCT05654623

Clinical benefit rate

Giredestrant
—Trial running · NCT06065748
Vepdegestrant
34.3% vs 28.7%vs Fulvestrantn 274NCT05654623
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Giredestrant: 3 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGiredestrantVepdegestrant
Dropout rate
8.7%a
NCT05659563 · Phase 2 · registry result, not featured evidence
7.8%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT05659563 · Phase 2 · registry result, not featured evidence
—a
NCT05549505 · Phase 2 · registry result, not featured evidence
Serious AEs
0%a
NCT05659563 · Phase 2 · registry result, not featured evidence
4%a
NCT05549505 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
arthralgia 9.5%
hot flush 9.5%
fatigue 7.1%
NCT05659563 · Phase 2 · registry result, not featured evidence
a
hot flush 24.8%
asthenia 20.8%
constipation 15.8%
NCT05549505 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Giredestrant

Ki67 -14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wk
absolute change · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence
Complete Cell Cycle Arrest 17.5% (n=40) vs 4.5% (n=44) Tamoxifen @ 2.14wk
absolute value · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence

Vepdegestrant

PFS 3.7 vs 3.6 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5 vs 2.1 Fulvestrant months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.9% (n=221) vs 3.6% (n=222) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 34.3% (n=274) vs 28.7% (n=272) Fulvestrant
responder rate · % of participants
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response NA vs 7.4 Fulvestrant months
time to event · months
NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Ki-67 Expression -71.4% (n=93) vs -72.9% (n=46) Anastrozole @ 2.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 71.4 Percent reduction as posted
Pathological Complete 1% (n=102) vs 0% (n=50) Anastrozole @ 22.57wk
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
mPEPI Score 0 20.6% (n=102) vs 20% (n=50) Anastrozole @ 22.57wk
event count · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
Breast Conserving Surgery 69.6% (n=102) vs 54% (n=50) Anastrozole
responder rate · % of participants
NCT05549505 · Phase 2 · registry result, not featured evidence
Stable Disease 37.3% (n=102) vs 32% (n=50) Anastrozole @ 24wk
event count · % of participants
Stable Disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
Progressive Disease 2.9% (n=102) vs 2% (n=50) Anastrozole @ 24wk
event count · % of participants
Progressive disease
NCT05549505 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Tumor Size -32.35% (n=45) vs -42.88% (n=19) Anastrozole @ 20.14wk
percent change · % of baseline
NCT05549505 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Vepdegestrant's landscape